JPRN-UMIN000038382招募中2 期
A phase II study of functional image-guided intensity-modulated radiotherapy for unresectable locally advanced lung cancer - FIGURE study
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Synchronous or metachronous (within 3 years) malignancies. 2. Active infection requiring systemic therapy. 3. Body temperature of 38 or more degrees Celsius. 4. Women during pregnancy or possible pregnancy, within 28 days after delivery, or during breast feeding. 5. Severe mental disease. 6. Receiving continuous systemic steroid or immune-suppressive medication. 7. Idiopathic pulmonary fibrosis on CT. 8. Severe cough requiring narcotic drugs.
研究者
相似试验
已完成
不适用
To evaluate efficacy of image-guided intensity modulated radiotherapy using fiducial gold markers for localized advanced prostate cancerProstate cancerJPRN-UMIN000006612Tohoku University60
招募中
2 期
A clinical trial to study the effects of special type of radiation therapy-Intensity modulated radiotherapy and image guided brachytherapy in cervical cancer.CTRI/2020/08/027434Dr Madhup Rastogi
招募中
3 期
A clinical trial to compare toxicity reduction between image guided intensity modulated radiotherapy (IG-IMRT) and conventional radiotherapy in Cancer Cervix (PARCER) patients.CTRI/2012/12/003249Tata Memorial Centre240
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1EUCTR2011-005437-39-BEJules Bordet Institute105
进行中（未招募）
1 期
Imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT (Imaging of the membranair receptor HER2 with the tracer zirconium 89 trastuzumab) and an early FDG-PET/CT response (early metabolic assessment) to identify patients with HER-2 positive invasive carcinoma of the breast with locally recurrent (not amenable to resection with curative intent) or metastatic disease unlikely to benefit from a novel anti-HER2 therapy: T-DM1ocally recurrent (not amenable to resection with curative intent) or metastatic disease scheduled for a first or any subsequent metastatic treatment lineMedDRA version: 19.0Level: PTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-005437-39-NLJules Bordet Institute105